The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

Slides:

Advertisements

Similar presentations

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

Advertisements

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,

A Phase II Study of Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia Xavier Badoux, William Wierda, Susan O'Brien,

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes by Rajendra N. Damle, Fabio.

EBV DNA: a Hodgkin lymphoma biomarker?

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

Rituximab-induced tumor cell agglutination

Tax fingerprint in adult T-cell leukemia

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

by Romina Gamberale, Jorge R. Geffner, Julieta Sanjurjo, Paula X

A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia by Gerald G. Wulf, Rui-Yu Wang, Ingrid Kuehnle, Douglas Weidner, Frank.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

by Rong Chen, Michael J. Keating, Varsha Gandhi, and William Plunkett

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia by Rossana Maffei, Silvia Martinelli,

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase.

Stage C or not stage C…? by Claire Dearden Blood

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

by Giridharan Ramsingh, Meagan A. Jacoby, Jin Shao, Rigoberto E

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent.

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

by Kamira Maharaj, John J

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients by Erica B. Esrick, John P. Manis,

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs by Preetesh Jain, Hagop Kantarjian,

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

Patient Tregs express normal levels of suppression.

Initial treatment of CLL: integrating biology and functional status

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance by Taghi Manshouri, Kim-anh.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia by Susan M. O'Brien, Nicole Lamanna, Thomas.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.

Cold agglutinin disease

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Presentation transcript:

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating, Taghi Manshouri, Francis J. Giles, Amanda Dey, Zeev Estrov, Charles A. Koller, Razelle Kurzrock, Deborah A. Thomas, Stefan Faderl, Susan Lerner, Susan O'Brien, and Maher Albitar Blood Volume 100(4): August 15, 2002 ©2002 by American Society of Hematology

Increased TNF-α plasma concentrations in patients having CLL.Comparison of TNF-α levels in 150 CLL patients and 20 healthy donors (P <.0001). Alessandra Ferrajoli et al. Blood 2002;100: ©2002 by American Society of Hematology

Correlation of TNF-α levels with Rai and Binet staging.TNF-α plasma levels in CLL patients according to Rai staging in all patients (panel A), of previously untreated patients (panel B), and according to Binet staging in all patients (panel C). Alessandra Ferrajoli et al. Blood 2002;100: ©2002 by American Society of Hematology

Correlation between CD38 expression and TNF-α.Scatter plot showing the correlation between CD38 expression in the leukemic cells and TNF-α levels. Alessandra Ferrajoli et al. Blood 2002;100: ©2002 by American Society of Hematology

Presence of high TNF-α levels in patients carrying unfavorable cytogenetic abnormalities.TNF-α plasma levels in CLL patients subdivided according to cytogenetic analysis. Alessandra Ferrajoli et al. Blood 2002;100: ©2002 by American Society of Hematology

Correlation between TNF-α level and survival duration.(A) Survival of the previously untreated CLL patients stratified by TNF-α level. Alessandra Ferrajoli et al. Blood 2002;100: ©2002 by American Society of Hematology